Brief: Enlaza Therapeutics Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers
02/09/2025 17:52
Sept 2 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: ENLAZA THERAPEUTICS: STRATEGIC COLLABORATION WITH VERTEX PHARMACEUTICALS TO DEVELOP WAR-LOCK DRUG CONJUGATES AND T-CELL ENGAGERS ENLAZA: WILL RECEIVE $45 MILLION INCLUSIVE OF AN UPFRONT PAYMENT AND EQUITY INVESTMENT ENLAZA: FURTHER ELIGIBLE TO RECEIVE MORE THAN $2 BILLION IN FUTURE MILESTONE PAYMENTS ENLAZA: VERTEX WILL FUND ALL RESEARCH AND DEVELOPMENT COSTS RELATED TO FOUR-YEAR COLLABORATION Source text: ID:nBw3srhWfa Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria